Studies from University of Oxford Describe New Findings in Cancer Gene Therapy (Combining virotherapy and angiotherapy for the treatment of breast cancer)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news originating from Oxford, United Kingdom, by NewsRx correspondents, research stated, "A breast cancer-selective oncolytic adenovirus was engineered to express antagonists of vascular endothelial growth factor (VEGF) and Notch signaling to combine direct anticancer activity with disruption of tumor-associated angiogenesis. Replication of the parental virus, AdEHE2F, is stimulated by estrogen receptor (ER), E2F1 and hypoxia, and it mediates selective lysis of breast cancer cells in vitro and in vivo."
Our news journalists obtained a quote from the research from the University of Oxford, "Here, we encoded soluble Flt-1 (sFlt1) and soluble Dll4 (sDll4) under control of the E3 promoter. sFlt1 (the extra-cellular domain of VEGF receptor 1) binds VEGF-A and inhibits stimulation of VEGFR2, decreasing angiogenic stimulus. Conversely, sDll4 (the extracellular domain of Delta-like 4) antagonizes Notch signaling to prevent endothelial maturation. We hypothesized that these agents might show additive or synergistic activity. In vitro, sFlt1 inhibited endothelial cell proliferation and sprouting, whereas sDll4 increased the number of vascular branchpoints. In ER-positive ZR75.1 tumors in vivo AdEHE2F showed the potent direct virotherapy with no augmentation owing to sFlt1 or sDll4; however, in ER-negative MDA-231 tumors efficacy was enhanced by encoding sFlt1 or sDll4, with survival time extending to double that of controls."
According to the news editors, the research concluded: "There was also a dramatic decrease in the total number of tumor blood vessels, as well as the number of perfused vessels, suggesting that improved efficacy reflects combined anti-tumour and anti-vascular effects."
For more information on this research see: Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Therapy, 2013;20(8):461-8. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)
The news correspondents report that additional information may be obtained from M. Bazan-Peregrino, Dept. of Oncology, Old Road Campus, University of Oxford, Oxford, UK. Additional authors for this research include R.C. Sainson, R.C. Carlisle, C. Thoma, R.A. Waters, C. Arvanitis, A.L. Harris, R. Hernandez-Alcoceba and L.W Seymour (see also Biotechnology).
Keywords for this news article include: VEGF, Biotechnology, Oxford, Europe, Oncology, Breast Cancer, United Kingdom, Women's Health, Membrane Proteins, Angiogenic Proteins, Cancer Gene Therapy, Growth Factor Receptors, Receptor Protein Tyrosine Kinases, Vascular Endothelial Growth Factors.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC